Professional Summary
Specializing In
Practice Locations
Patient Ratings
Referring Physicians
Professional Summary
Education & Certifications
- Fellowship: Stanford University Hematology and Oncology Fellowship (2006) CA
- Medical Education: Albany Medical College Office of the Registrar (1998) NY
- Board Certification: American Board of Internal Medicine, Medical Oncology (2004)
- Board Certification: American Board of Internal Medicine, Internal Medicine (2001)
- Residency: Warren Alpert Medical School Brown University (2001) RI
- Internship: Warren Alpert Medical School Brown University (1999) RI
- A.B., Harvard College, Biophysics (1994)
Honors & Awards
- Career Development Award, ConquerCancer/ASCO (2016-2019)
- Center for Cancer Nanotechnology Excellence: leader of the Clinical Translational Core, NIH/NCI (2015-2020)
- Dean's Fellowship, Stanford School of Medicine (April 2004- March 2005)
- Developmental Cancer Research Award, Stanford Cancer Institute (September 2011-August 2012)
- Early Detection of Hereditary Renal Cancer (RCC) Pilot Grant, International Alliance for Cancer Early Detection (June 2020-May 2021)
- Innovation Award, Stanford Cancer Institute (2014-2016)
- K23 Career Development Award, NIH/NCI (July 2010-June 2015)
- R21: Analysis of CTCs for Early Prediction of Response to Treatment in RCC, NIH/NCI (2014-2016)
- R21: Nanoscale proteomic profiles of hypoxia pathways to develop biomarkers of renal cell carcinoma, NIH/NCI (August 2012-July 2014)
- Research Fellowship, Lymphoma Research Foundation (July 2004-June 2006)
- Special Fellow in Clinical Research, Leukemia and Lymphoma Society (July 2006-June 2009)
- TRAM Renewal Grant: Development of blood biomarkers for diagnosis and monitoring of kidney cancer, Stanford Department of Medicine (October 2012-August 2013)
- Translational Research and Applied Medicine Program (TRAM) Pilot Grant, Stanford Department of Medicine (October 2011-September 2012)
Administrative Appointments
- Associate Member, Stanford Cancer Institute Translational Oncology Program (2008 - Present)
- Clinical Mentor, Stanford Molecular Imaging Scholars Program (2010 - Present)
- co-Director, Translational Investigator Program, Department of Medicine, Stanford School of Medicine (2022 - Present)
- Director, "Frontiers in Cancer Clinical Translation" Seminar Series, Division of Oncology, Stanford School of Medicine (2020 - Present)
- Faculty Fellow, ChemH [Chemistry, Engineering & Medicine for Human Health Institute] (2018 - Present)
- Faculty Member, Canary Center, Stanford Radiology (2017 - Present)
- Founding Advisor, Stanford Association for Multidisciplinary Medicine and Science (2008 - 2013)
- Inteviewer, Stanford School of Medicine Internal Medicine Residency (2011 - Present)
- Member, Stanford Lymphoma Disease Management Group (2005 - 2013)
- Member, Stanford Kidney Cancer Research Group (2011 - Present)
- Member, Stanford BioX Program (2016 - Present)
- Research Mentor, NIH/NIDDK Short term education program for under-represented persons (2011 - 2011)
- Research Mentor, Canary Cancer Research Education Summer Training (CREST) Program (2019 - Present)
Publications
-
p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma
King, T. C., Akerley, W., Fan, A. C., Moore, T., Mangray, S., Chen, M. H., & Safran, H. (2000). p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma. CANCER, 89(4), 769–773. -
Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer
Giuriato, S., Rabin, K., Fan, A. C., Shachaf, C. M., & Felsher, D. W. (2004). Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer. SEMINARS IN CANCER BIOLOGY, 14(1), 3–11. -
Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch
Giuriato, S., Ryeom, S., Fan, A. C., Bachireddy, P., Lynch, R. C., Rioth, M. J., … Felsher, D. W. (2006). Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 103(44), 16266–71. -
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis
Shachaf, C. M., Perez, O. D., Youssef, S., Fan, A. C., Elchuri, S., Goldstein, M. J., … Felsher, D. W. (2007). Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. BLOOD, 110(7), 2674–84. -
Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation
Wu, C.-H., van Riggelen, J., Yetil, A., Fan, A. C., Bachireddy, P., & Felsher, D. W. (2007). Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 104(32), 13028–33. -
Combined Inactivation of MYC and K-Ras Oncogenes Reverses Tumorigenesis in Lung Adenocarcinomas and Lymphomas
Tran, P. T., Fan, A. C., Bendapudi, P. K., Koh, S., Komatsubara, K., Chen, J., … Felsher, D. W. (2008). Combined Inactivation of MYC and K-Ras Oncogenes Reverses Tumorigenesis in Lung Adenocarcinomas and Lymphomas. PLOS ONE, 3(5). -
A quantitative PCR method to detect blood microRNAs associated with tumorigenesis in transgenic mice
Fan, A. C., Goldrick, M. M., Ho, J., Liang, Y., Bachireddy, P., & Felsher, D. W. (2008). A quantitative PCR method to detect blood microRNAs associated with tumorigenesis in transgenic mice. MOLECULAR CANCER, 7. -
Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds
Kampa, K. M., Acoba, J. D., Chen, D., Gay, J., Lee, H., Beemer, K., … Lopez, C. D. (2009). Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 106(11), 4390–95. -
Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens
Fan, A. C., Deb-Basu, D., Orban, M. W., Gotlib, J. R., Natkunam, Y., O'Neill, R., … Felsher, D. W. (2009). Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. NATURE MEDICINE, 15(5), 566–71. -
Supramolecular Stacking of Doxorubicin on Carbon Nanotubes for In Vivo Cancer Therapy
Liu, Z., Fan, A. C., Rakhra, K., Sherlock, S., Goodwin, A., Chen, X., … Dai, H. (2009). Supramolecular Stacking of Doxorubicin on Carbon Nanotubes for In Vivo Cancer Therapy. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 48(41), 7668–72. -
Definition of an Enhanced Immune Cell Therapy in Mice That Can Target Stem-Like Lymphoma Cells
Contag, C. H., Sikorski, R., Negrin, R. S., Schmidt, T., Fan, A. C., Bachireddy, P., … Thorne, S. H. (2010). Definition of an Enhanced Immune Cell Therapy in Mice That Can Target Stem-Like Lymphoma Cells. CANCER RESEARCH, 70(23), 9837–45. -
CD4(+) T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation
Rakhra, K., Bachireddy, P., Zabuawala, T., Zeiser, R., Xu, L., Kopelman, A., … Felsher, D. W. (2010). CD4(+) T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation. CANCER CELL, 18(5), 485–98. -
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na
Seetharam, M., Fan, A. C., Tran, M., Xu, L., Renschler, J. P., Felsher, D. W., … Greenberg, P. L. (2012). Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. LEUKEMIA RESEARCH, 36(1), 98–103. -
"Picolog," a Synthetically-Available Bryostatin Analog, Inhibits Growth of MYC-Induced Lymphoma In Vivo
DeChristopher, B. A., Fan, A. C., Felsher, D. W., & Wender, P. A. (2012). "Picolog," a Synthetically-Available Bryostatin Analog, Inhibits Growth of MYC-Induced Lymphoma In Vivo. ONCOTARGET, 3(1), 58–66. -
Cryptococcal osteomyelitis and meningitis in a patient with non-hodgkin's lymphoma treated with PEP-C.
To, C. A., Hsieh, R. W., McClellan, J. S., Howard, W., Fischbein, N. J., Brown, J. M. Y., … Fan, A. C. (2012). Cryptococcal osteomyelitis and meningitis in a patient with non-hodgkin's lymphoma treated with PEP-C. BMJ Case Reports, 2012. -
A novel nano-immunoassay system capable of absolute protein measurements from 400 tumor-derived stem cells.
Voehringer, D. W., Deb-Basu, D., Weissman, I., Fan, A., Nguyen, U., Bhamidipati, A., & Felsher, D. W. (2007). A novel nano-immunoassay system capable of absolute protein measurements from 400 tumor-derived stem cells. MOLECULAR CANCER THERAPEUTICS, 6(12), 3556S–3556S. -
ABT-737 Targets Leukemic Stem Cells In Mouse Models of Mutant NRASD12/hBCL-2-Mediated Acute Myeloid Leukemia progression with Increased Survival
Padua, R. A., Beurlet, S., Krief, P., Omidvar, N., Le Pogam, C., Auboeuf, D., … Chomienne, C. (2010). ABT-737 Targets Leukemic Stem Cells In Mouse Models of Mutant NRASD12/hBCL-2-Mediated Acute Myeloid Leukemia progression with Increased Survival. BLOOD, 116(21), 1355–56. -
ASPP2 haploinsufficiency promotes tumor formation in a mouse model.
Kampa, K. M., Acoba, J. D., Chen, D., Beemer, K., Gay, J., Zhu, Z., … Lopez, C. D. (2006). ASPP2 haploinsufficiency promotes tumor formation in a mouse model. BLOOD, 108(11), 162B–162B. -
A Novel Nano-Immunoassay (NIA) Reveals Inhibition of PI3K and MAPK Pathways in CD34+Bone Marrow Cells of Patients with Myelodysplastic Syndrome (MDS) Treated with the Multi-Kinase Inhibitor On 01910.Na (Rigosertib)
Fan, A. C., Xu, L., Sridhar, K. J., Tran, M., Banerjee, P., Renschler, J. P., … Felsher, D. W. (2011). A Novel Nano-Immunoassay (NIA) Reveals Inhibition of PI3K and MAPK Pathways in CD34+Bone Marrow Cells of Patients with Myelodysplastic Syndrome (MDS) Treated with the Multi-Kinase Inhibitor On 01910.Na (Rigosertib). BLOOD, 118(21), 1626–26. -
Treatment of Higher Risk Myelodysplastic Syndrome Patients Unresponsive to Hypomethylating Agents with ON 01910.Na
Seetharam, M., Tran, M., Fan, A. C., Xu, L., Renschler, J. P., Felsher, D. W., … Greenberg, P. L. (2010). Treatment of Higher Risk Myelodysplastic Syndrome Patients Unresponsive to Hypomethylating Agents with ON 01910.Na. BLOOD, 116(21), 1635–35. -
A c-Myc Activation Sensor-Based High-Throughput Drug Screening Identifies an Antineoplastic Effect of Nitazoxanide.
Fan-Minogue, H., Bodapati, S., Solow-Cordero, D., Fan, A., Paulmurugan, R., Massoud, T. F., … Gambhir, S. S. (2013). A c-Myc Activation Sensor-Based High-Throughput Drug Screening Identifies an Antineoplastic Effect of Nitazoxanide. Molecular Cancer Therapeutics, 12(9), 1896–1905. -
BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells.
Beurlet, S., Omidvar, N., Gorombei, P., Krief, P., Le Pogam, C., Setterblad, N., … Padua, R. A. (2013). BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. Blood, 122(16), 2864–76. -
Oncogene withdrawal engages the immune system to induce sustained cancer regression.
Casey, S. C., Li, Y., Fan, A. C., & Felsher, D. W. (2014). Oncogene withdrawal engages the immune system to induce sustained cancer regression. Journal for Immunotherapy of Cancer, 2, 24-? -
Alteration of the lipid profile in lymphomas induced by MYC overexpression.
Eberlin, L. S., Gabay, M., Fan, A. C., Gouw, A. M., Tibshirani, R. J., Felsher, D. W., & Zare, R. N. (2014). Alteration of the lipid profile in lymphomas induced by MYC overexpression. Proceedings of the National Academy of Sciences of the United States of America, 111(29), 10450–55. -
Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.
Fan, A. C., O'Rourke, J. J., Praharaj, D. R., & Felsher, D. W. (2013). Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer. Expert Opinion on Investigational Drugs, 22(11), 1495–1509. -
BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia.
Li, Y., Deutzmann, A., Choi, P. S., Fan, A. C., & Felsher, D. W. (2016). BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia. Oncotarget. -
BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia
Li, Y., Deutzmann, A., Choi, P. S., Fan, A. C., & Felsher, D. W. (2016). BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia. ONCOTARGET, 7(19), 26926–34. -
KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.
Swords, R. T., Greenberg, P. L., Wei, A. H., Durrant, S., Advani, A. S., Hertzberg, M. S., … Lancet, J. E. (2016). KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. Leukemia Research, 50, 123–31. -
Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer.
Narayanan, S., Lam, A., Vaishampayan, U., Harshman, L., Fan, A., Pachynski, R., … Srinivas, S. (2016). Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer. Clinical Genitourinary Cancer, 14(5), 432–37. -
High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.
Sharma, A., Burridge, P. W., McKeithan, W. L., Serrano, R., Shukla, P., Sayed, N., … Wu, J. C. (2017). High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. Science Translational Medicine, 9(377). -
Consolidative Radiotherapy in Metastatic Urothelial Cancer.
Shah, S., Zhang, C. A., Hancock, S., Fan, A., Skinner, E., & Srinivas, S. (2017). Consolidative Radiotherapy in Metastatic Urothelial Cancer. Clinical Genitourinary Cancer. -
Monitoring Neutropenia for Cancer Patients at the Point of Care
Inan, H. (2017). Monitoring Neutropenia for Cancer Patients at the Point of Care. Small Methods. -
Consolidative radiotherapy in metastatic urothelial cancer (MUC)
Srinivas, S., Narayanan, S., Fan, A. C., Hancock, S. L., & Skinner, E. C. (2016). Consolidative radiotherapy in metastatic urothelial cancer (MUC). JOURNAL OF CLINICAL ONCOLOGY, 34(2). -
Use of nano-immuno assay to generate rapid, quantitative nanoscale proteomic profiling of the hypoxia pathway in renal cell carcinoma clinical specimens.
Fan, A. C., Banerjee, P., Leppert, J., Harshman, L. C., Sabatti, C., Brooks, J. D., & Felsher, D. W. (2012). Use of nano-immuno assay to generate rapid, quantitative nanoscale proteomic profiling of the hypoxia pathway in renal cell carcinoma clinical specimens. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
NANO-SCALE PROTEOMIC PROFILING TO DEFINE DIAGNOSTIC SIGNATURES AND BIOMARKERS OF THERAPEUTIC ACTIVITY IN RCC
Leppert, J., Fan, A., Liliental, J., Xu, L., Thong, A., Yost, C., … Felsher, D. (2013). NANO-SCALE PROTEOMIC PROFILING TO DEFINE DIAGNOSTIC SIGNATURES AND BIOMARKERS OF THERAPEUTIC ACTIVITY IN RCC. JOURNAL OF UROLOGY. ELSEVIER SCIENCE INC. -
INTRA-TUMOR HETEROGENEITY IN RENAL CELL CARCINOMA: IMPLICATIONS FOR PROTEOMIC ANALYSIS OF RENAL MASS BIOPSIES
Massoudi, R., Hoerner, C., Metzner, T., O'Rourke, J., Curtis, R., Stell, L., … Leppert, J. (2017). INTRA-TUMOR HETEROGENEITY IN RENAL CELL CARCINOMA: IMPLICATIONS FOR PROTEOMIC ANALYSIS OF RENAL MASS BIOPSIES. JOURNAL OF UROLOGY. ELSEVIER SCIENCE INC. -
Clinicopathologic Characteristics of Fumarate Hydratase-Deficient and Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Series of 10 Cases
Lau, H., Williamson, S. R., Kunder, C., Fan, A. C., & Kao, C.-S. (2018). Clinicopathologic Characteristics of Fumarate Hydratase-Deficient and Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Series of 10 Cases. MODERN PATHOLOGY. NATURE PUBLISHING GROUP. -
KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study (vol 50, pg 123, 2016)
Swords, R. T., Greenberg, P. L., Wei, A. H., Durrant, S., Advani, A. S., Hertzberg, M. S., … Lancet, J. E. (2017). KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study (vol 50, pg 123, 2016). LEUKEMIA RESEARCH, 59, 65. -
Serum miR371a Quantitation for Assessing Tumor Burden in Testicular Germ Cell Tumors
Kunder, C., Imae, Y., Srinivas, S., & Fan, A. C. (2018). Serum miR371a Quantitation for Assessing Tumor Burden in Testicular Germ Cell Tumors. MODERN PATHOLOGY, 31, 703. -
Nano-scale phospho-proteomic analysis to define diagnostic signatures and biomarkers of therapeutic activity in cancer
Fan, A. C., Banerjee, P., Xu, L., Kong, C., Sabatti, C., Wilheim, F., … Felsher, D. W. (2012). Nano-scale phospho-proteomic analysis to define diagnostic signatures and biomarkers of therapeutic activity in cancer. CANCER RESEARCH, 72. -
Clinicopathologic Characteristics of Fumarate Hydratase-Deficient and Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Series of 10 Cases
Lau, H., Williamson, S. R., Kunder, C., Fan, A. C., & Kao, C.-S. (2018). Clinicopathologic Characteristics of Fumarate Hydratase-Deficient and Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Series of 10 Cases. LABORATORY INVESTIGATION. NATURE PUBLISHING GROUP. -
The 'Achilles Heel' of Metabolism in Renal Cell Carcinoma: Glutaminase Inhibition as a Rational Treatment Strategy.
Hoerner, C. R., Chen, V. J., & Fan, A. C. (2019). The 'Achilles Heel' of Metabolism in Renal Cell Carcinoma: Glutaminase Inhibition as a Rational Treatment Strategy. Kidney Cancer, 3(1), 15–29. -
18F-FPPRGD2 PET/CT in patients with metastatic renal cell cancer.
Toriihara, A., Duan, H., Thompson, H. M., Park, S., Hatami, N., Baratto, L., … Iagaru, A. (2019). 18F-FPPRGD2 PET/CT in patients with metastatic renal cell cancer. European Journal of Nuclear Medicine and Molecular Imaging. -
Serum miR371a Quantitation for Assessing Tumor Burden in Testicular Germ Cell Tumors
Kunder, C., Imae, Y., Srinivas, S., & Fan, A. C. (2018). Serum miR371a Quantitation for Assessing Tumor Burden in Testicular Germ Cell Tumors. LABORATORY INVESTIGATION. NATURE PUBLISHING GROUP. -
Phase II study of pazopanib with weekly paclitaxel in refractory urothelial cancer.
Srinivas, S., Narayanan, S., Harshman, L. C., Pachynski, R. K., Lam, A. P., Fan, A. C., … Vaishampayan, U. N. (2015). Phase II study of pazopanib with weekly paclitaxel in refractory urothelial cancer. JOURNAL OF CLINICAL ONCOLOGY, 33(7). -
Nanoscale proteomic profiling to define diagnostic signatures and biomarkers of therapeutic activity in patients with RCC
Fan, A. C., Leppert, J., Liliental, J. E., Xu, L., Thong, A. E., Yost, C., … Felsher, D. W. (2013). Nanoscale proteomic profiling to define diagnostic signatures and biomarkers of therapeutic activity in patients with RCC. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Pilot study of F-18-FSPG vs F-18-FDG PET imaging for response assessment in cancer
Park, S., Hatami, N., Rutledge, O., Koglin, N., Loo, B., Fan, A., & Mittra, E. (2017). Pilot study of F-18-FSPG vs F-18-FDG PET imaging for response assessment in cancer. JOURNAL OF NUCLEAR MEDICINE, 58. -
A nano-immunoassay system for monitoring changes in signaling upon oncogene inactivation in hematopoietic tumors
Fan, A. C., Deb-Basu, D., Gotlib, J., Voehringer, D. W., & Felsher, D. W. (2007). A nano-immunoassay system for monitoring changes in signaling upon oncogene inactivation in hematopoietic tumors. MOLECULAR CANCER THERAPEUTICS, 6(12), 3610S. -
Nano-fluidic detection of oncoprotein signaling in preclinical and patient lymphoma samples.
Fan, A. C., Deb-Basu, D., Horoschak, M., Shirer, A., Voehringer, D., O'Neill, R., & Felsher, D. W. (2006). Nano-fluidic detection of oncoprotein signaling in preclinical and patient lymphoma samples. BLOOD, 108(11), 715A. -
Two oncogenic hits are required to initiate lymphomagenesis in adult, but not neonatal hosts.
Fan, A. C., Giuriato, S., Karlsson, A., Padua, R. A., & Felsher, D. W. (2005). Two oncogenic hits are required to initiate lymphomagenesis in adult, but not neonatal hosts. BLOOD, 106(11), 732A. -
Cooperation between MYC and BCL2 to induce lymphoma is uncovered in an adult context
Fan, A. C., Giuriato, S., Feng, C., Padua, R. A., & Felsher, D. (2004). Cooperation between MYC and BCL2 to induce lymphoma is uncovered in an adult context. BLOOD, 104(11), 429A. -
MYC or RAS, but not BCL2 expression induces reversible lymphomagenesis
Fan, A. C., Giuriato, S., Karlsson, A., Bachireddy, P., Bendapudi, P., Rakhra, K., … Felsher, D. (2006). MYC or RAS, but not BCL2 expression induces reversible lymphomagenesis. CANCER RESEARCH, 66(8). -
Nanoliter-scale Western-blot-like BCL-2 analysis of lymphoma fine needle aspirates
Fan, A. C., Voehringer, D., Deb-Basu, D., Gossett, J., O-Neill, R., & Felsher, D. W. (2006). Nanoliter-scale Western-blot-like BCL-2 analysis of lymphoma fine needle aspirates. CANCER RESEARCH, 66(8). -
MYC quantification in lymphoma fine needle aspirates using "Firefly," a novel nanofluidic protein analysis system
Fan, A. C., Voehringer, D., Deb-Basu, D., Gossett, J., O'Neill, R., & Felsher, D. (2006). MYC quantification in lymphoma fine needle aspirates using "Firefly," a novel nanofluidic protein analysis system. CANCER RESEARCH, 66(8). -
Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC).
Tannir, N. M., Fan, A. C., Lee, R. J., Carthon, B. C., Iliopoulos, O., Mier, J. W., … Bauer, T. M. (2018). Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
A rapid screening method for monitoring signaling changes in the monocyte cell line U937
Huang, Y.-W., Shahijanian, F., Deb-Basu, D., Fan, A., Voehringer, D., & Hirschberg, D. (2009). A rapid screening method for monitoring signaling changes in the monocyte cell line U937. CANCER RESEARCH, 69. -
The Simple Western rapidly generates quantitative profiles of MAPK and PI3K proteins in clinical specimens
Fan, A. C., Banerjee, P., & Felsher, D. W. (2012). The Simple Western rapidly generates quantitative profiles of MAPK and PI3K proteins in clinical specimens. CANCER RESEARCH, 72. -
Defining the genetic contexts when MYC inactivation induces sustained regression of hematopoietic tumors.
Giuriato, S., Passegue, E., Fan, A., Tang, F., & Felsher, D. W. (2003). Defining the genetic contexts when MYC inactivation induces sustained regression of hematopoietic tumors. BLOOD, 102(11), 586A. -
Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations
Carneiro, B. A., Collier, K. A., Nagy, R. J., Pamarthy, S., Sagar, V., Fairclough, S., … Giles, F. J. (2018). Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations. JCO PRECISION ONCOLOGY, 2. -
Monitoring Neutropenia for Cancer Patients at the Point of Care.
Inan, H., Kingsley, J. L., Ozen, M. O., Tekin, H. C., Hoerner, C. R., Imae, Y., … Demirci, U. (2017). Monitoring Neutropenia for Cancer Patients at the Point of Care. Small Methods, 1(9). -
A phase 1/2 study of CB-839, a first-in-class glutaminase inhibitor, combined with nivolumab in patients with advanced melanoma (MEL), renal cell carcinoma (RCC), or non-small cell lung cancer (NSCLC)
Meric-Bernstam, F., Gordon, M., Tykodi, S., Lam, E., Vaishampayan, U., Chaves, J., … Voss, M. (2017). A phase 1/2 study of CB-839, a first-in-class glutaminase inhibitor, combined with nivolumab in patients with advanced melanoma (MEL), renal cell carcinoma (RCC), or non-small cell lung cancer (NSCLC). JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMC. -
F-18-FPPRGD(2) PET/CT in patients with metastatic renal cell cancer
Toriihara, A., Duan, H., Park, S., Hatami, N., Baratto, L., Fan, A., & Iagaru, A. (2018). F-18-FPPRGD(2) PET/CT in patients with metastatic renal cell cancer. JOURNAL OF NUCLEAR MEDICINE, 59. -
Economic burden of empiric drug utilization in metastatic renal cell carcinoma emphasizes the need for early biomarkers of response.
Chen, V., Gong, C., Zhang, C. A., Srinivas, S., Lee, H. E., & Fan, A. C. (2017). Economic burden of empiric drug utilization in metastatic renal cell carcinoma emphasizes the need for early biomarkers of response. JOURNAL OF CLINICAL ONCOLOGY, 35. -
Early Changes in CT Perfusion Parameters: Primary Renal Carcinoma Versus Metastases After Treatment with Targeted Therapy
Fan, A. C., Sundaram, V., Kino, A., Schmiedeskamp, H., Metzner, T. J., & Kamaya, A. (2019). Early Changes in CT Perfusion Parameters: Primary Renal Carcinoma Versus Metastases After Treatment with Targeted Therapy. CANCERS, 11(5). -
Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell Carcinoma.
Chen, V. J., Hernandez-Meza, G., Agrawal, P., Zhang, C. A., Xie, L., Gong, C. L., … Fan, A. C. (2019). Time on Therapy for at Least Three Months Correlates with Overall Survival in Metastatic Renal Cell Carcinoma. Cancers, 11(7). -
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC)
Meric-Bernstam, F., Tannir, N. M., Mier, J. W., DeMichele, A., Telli, M. L., Fan, A. C., … Harding, J. J. (2016). Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC). JOURNAL OF CLINICAL ONCOLOGY, 34(15). -
Multiregion Quantification of Extracellular Signal-regulated Kinase Activity in Renal Cell Carcinoma.
Hoerner, C. R., Massoudi, R., Metzner, T. J., Stell, L., O'Rourke, J. J., Kong, C. S., … Fan, A. C. (2018). Multiregion Quantification of Extracellular Signal-regulated Kinase Activity in Renal Cell Carcinoma. European Urology Oncology. -
Postmarketing Analysis of Sipuleucel-T-The Importance of Real-World Data.
Fan, A. C., & Leppert, J. T. (2019). Postmarketing Analysis of Sipuleucel-T-The Importance of Real-World Data. JAMA Network Open, 2(8), e199233. -
Prognostic factors for pancreatic metastases in renal cell cancer.
Chung, A., Li, S., Shah, S., Fan, A. C., & Srinivas, S. (2016). Prognostic factors for pancreatic metastases in renal cell cancer. JOURNAL OF CLINICAL ONCOLOGY, 34(15). -
A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-Deficient Renal Cell Carcinoma in 32 Patients.
Lau, H. D., Chan, E., Fan, A. C., Kunder, C. A., Williamson, S. R., Zhou, M., … Kao, C.-S. (2019). A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-Deficient Renal Cell Carcinoma in 32 Patients. The American Journal of Surgical Pathology. -
Routine plasma-based genotyping to comprehensively detect germline, somatic, and reversion BRCA mutations among patients with advanced solid tumors.
Vidula, N., Rich, T. A., Sartor, O., Yen, J., Hardin, A., Nance, T., … Cristofanilli, M. (2020). Routine plasma-based genotyping to comprehensively detect germline, somatic, and reversion BRCA mutations among patients with advanced solid tumors. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Feasibility and design of a cloud-based digital platform in patients with advanced cancer.
Roy, M., Hall, E. T., Velazquez, B., Shah, S., Fardeen, T., Cunanan, K., … Ramchandran, K. (2019). Feasibility and design of a cloud-based digital platform in patients with advanced cancer. JOURNAL OF CLINICAL ONCOLOGY, 37(27). -
Landscape of BRCA1 and BRCA2 germline, somatic, and reversion alterations detectable by cell-free DNA testing among patients with metastatic breast, ovarian, pancreatic, or prostate cancer
Bardia, A., Rich, T. A., Raymond, V. M., Fairclough, S. R., Sartor, A. O., Lilly, M. B., … Cristofanilli, M. (2018). Landscape of BRCA1 and BRCA2 germline, somatic, and reversion alterations detectable by cell-free DNA testing among patients with metastatic breast, ovarian, pancreatic, or prostate cancer. JOURNAL OF CLINICAL ONCOLOGY, 36(15). -
Therapeutic benefit of empiric drug sequencing in metastatic renal cell carcinoma
Chen, V., Gong, C., Hoerner, C. R., Zhang, C. A., Srinivas, S., & Fan, A. C. (2018). Therapeutic benefit of empiric drug sequencing in metastatic renal cell carcinoma. JOURNAL OF CLINICAL ONCOLOGY, 36(15). -
Targeting Metabolic Pathways in Kidney Cancer: Rationale and Therapeutic Opportunities.
Hoerner, C. R., Miao, S. Y., Hsieh, J. J., & Fan, A. C. Targeting Metabolic Pathways in Kidney Cancer: Rationale and Therapeutic Opportunities. Cancer Journal (Sudbury, Mass.), 26(5), 407–18. -
Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma.
Hirotsu, K. E., Rana, J., Wang, J. Y., Raghavan, S. S., Rieger, K. E., Srinivas, S., … Zaba, L. (2020). Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma. Journal of the American Academy of Dermatology. -
Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring.
Nesvet, J. C., Antilla, K. A., Pancirer, D. S., Lozano, A. X., Preiss, J. S., Ma, W., … Wang, S. X. (2021). Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring. Clinical Chemistry. -
In Search of Clinical Biomarkers of Response to Checkpoint Inhibitor Therapy in Renal Cell Carcinoma.
Fan, A. C., & Leppert, J. T. (2021). In Search of Clinical Biomarkers of Response to Checkpoint Inhibitor Therapy in Renal Cell Carcinoma. JAMA Network Open, 4(1), e2035120. -
Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors.
Waliany, S., Neal, J. W., Reddy, S., Wakelee, H., Shah, S. A., Srinivas, S., … Zhu, H. (2021). Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors. JACC. CardioOncology, 3(1), 137–39. -
Return of individual research results: What do participants prefer and expect?
Sayeed, S., Califf, R., Green, R., Wong, C., Mahaffey, K., Gambhir, S. S., … Wong, C. A. (2021). Return of individual research results: What do participants prefer and expect? PloS One, 16(7), e0254153. -
Implementation of a cloud-based electronic patient-reported outcome (ePRO) platform in patients with advanced cancer.
Generalova, O., Roy, M., Hall, E., Shah, S. A., Cunanan, K., Fardeen, T., … Ramchandran, K. (2021). Implementation of a cloud-based electronic patient-reported outcome (ePRO) platform in patients with advanced cancer. Journal of Patient-Reported Outcomes, 5(1), 91. -
The 'Achilles Heel' of Metabolism in Renal Cell Carcinoma: Glutaminase Inhibition as a Rational Treatment Strategy
Hoerner, C. R., Chen, V. J., & Fan, A. C. (2019). The 'Achilles Heel' of Metabolism in Renal Cell Carcinoma: Glutaminase Inhibition as a Rational Treatment Strategy. KIDNEY CANCER, 3(1), 15–29. -
Clinical laboratory tests associated with survival in patients with metastatic renal cell carcinoma: A Laboratory Wide Association Study (LWAS).
Velaer, K., Thomas, I.-C. C., Yang, J., Kapphahn, K., Metzner, T. J., Golla, A., … Leppert, J. T. (2021). Clinical laboratory tests associated with survival in patients with metastatic renal cell carcinoma: A Laboratory Wide Association Study (LWAS). Urologic Oncology. -
Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer
Gupta, D., Fardeen, T., Teuteberg, W., Seevaratnam, B., Asuncion, M. K., Alves, N., … Ramchandran, K. (2021). Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Telaglenastat Plus Cabozantinib or Everolimus For Advanced or Metastatic Renal Cell Carcinoma: an Open-Label Phase 1 Trial.
Meric-Bernstam, F., Tannir, N. M., Lliopoulos, O., Lee, R. J., Telli, M. L., Fan, A. C., … Bauer, T. M. (2022). Telaglenastat Plus Cabozantinib or Everolimus For Advanced or Metastatic Renal Cell Carcinoma: an Open-Label Phase 1 Trial. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Association of renal cell carcinoma (RCC) metastatic to pancreas with a distinct molecular profile and immune cell population.
Chiang, R. S., Ashok, A., Mauer, E., Barrett, A., Hoerner, C. R., Khan, O. A., … Khaki, A. R. (2022). Association of renal cell carcinoma (RCC) metastatic to pancreas with a distinct molecular profile and immune cell population. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Utilizing the autoantibody immune response to tumor antigens for kidney cancer early detection.
Hoerner, C. R., Jhatro, M., Waitz, R., Kamath, K., Zhang, M., Dhal, A., … Fan, A. C. (2022). Utilizing the autoantibody immune response to tumor antigens for kidney cancer early detection. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial.
Lee, C.-H. H., Motzer, R., Emamekhoo, H., Matrana, M., Percent, I., Hsieh, J. J., … Tannir, N. M. (2022). Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial.
Archer, S., Fennell, N., Colvin, E., Laquindanum, R., Mills, M., Dennis, R., … Tischkowitz, M. (2022). Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial. Cancers, 14(11). -
Personalised risk prediction in hereditary breast and ovarian cancer: A protocol for a multi-centre randomised controlled trial
Fennell, N., Colvin, E., Laquindanum, R., Mills, M., Dennis, R., Donoso, F. S., … Archer, S. (2022). Personalised risk prediction in hereditary breast and ovarian cancer: A protocol for a multi-centre randomised controlled trial. PSYCHO-ONCOLOGY. WILEY. -
Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer.
Gensheimer, M. F., Gupta, D., Patel, M. I., Fardeen, T., Hildebrand, R., Teuteberg, W., … Ramchandran, K. (2022). Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer. JCO Oncology Practice, OP2200128. -
The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity
Huang, Y. V., Waliany, S., Lee, D., Galdos, F. X., Witteles, R. M., Neal, J. W., … Zhu, H. (2022). The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity. JACC: CardioOncology, 4(5).
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts
- Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
- Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors
- Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
- Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
- Phase 2 Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma
- A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)
- Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma
Practice Locations
Urologic Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CA
Urologic Cancer Program in Palo Alto
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereNeurogenetic Cancer Palo Alto, CA
Palo Alto, CA
Neurogenetic Cancer
213 Quarry Road
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(172 reviews)
Dr. Fan is a superb professional, outstanding in her knowledge of the medical matters at hand and superb in her personal sensitivity to working with patients— and especially so when discussing medical matters bearing grave consequences. She is a superb representative of Stanford
University's commitment to excellence.
Very happy with Dr Fan as my doctor!
She seems honorable
Very gracious and helpfull
She's great! And her Fellow assisting was good, too!
We appreciated Dr Fan’s depth of knowledge and the way she explained everything was so helpful in our decision making process. She gave us confidence we hadn’t experienced with other doctors.
Listens carefully and explains everything very well. I would highly recommend her!!
Best possible care
Great doctor … Dr. Fan is very clear in both the cause and the solution to my illness
A superb physician in every respect: generous spirited and yet focused during our conversation. Supportive and encouraging in her observations — without distracting from the focus of our conversation. Specific and clear — and concrete — in her observations and recommendations. An engaging conversationalist who never loses sight of the focus of her observations. In all respects, a superb professional who exemplifies the best of science and humanistic attention to patients.
Dr. Fan cares about her patients and takes the time to listen and explain questions, and gives you the choice to participate in future pan of action. Plus she is very pleasant and a joy to work with.
Dr. Fan is a very nice doctor, and give me a lot of help.
Very friendly and helpful
Extremely good at explaining what and why the test, procedures or prescriptions are for and why they are needed. She helped to be confident that everything was going to come out well.
Affable, knowledgable, wonderful.
Felt listened to and understood by Dr. Fan. Good conversation.
She's great! Give her a raise!
Dr Fan is an outstanding researcher and physician.
Dr. Fan was great! She answered all my questions, explained upcoming procedures and what I can expect in the next few months.
She seems very good.
Doctor Fan is very professional, is always able to answer all my questions, she is very patient and always take her time to explain all my concerns. Thank you Doctor Fan.
Dr. Fan is very kind and listens very well. Very encouraging and sets aside plenty of time for questions. She explains all options and alternatives.
I look forward to working with Dr. Fan and her Team.
Obviously brilliant, pleasant, reassuring - and actively seeks patient's input and concerns - not necessarily common with many doctors.
Dr. Fan is a knowledgeable and compassionate doctor.
Very nice and detail.
Dr. Fan is very clear and concise, right on to the point of patient care with updated treatment information, options, and measures. which gave me more confidence in combating the disease. Way beyond my expectation.
Very thankful.
Dr. Fan seems very caring and eager to help me with my medical problems.
She's great! Give her a raise! (This also includes her team, especially Ms Mika Shann Ruiz...)
She is compassionate, bright, articulate, and very knowledgeable, and I am very lucky to have her as my physician. Her staff is excellent to.
She was informative and helpful in me understanding my initial diagnosis.
She is very professional and always is concerned about my health.
Superb communicator and extremely knowledgeable about all facets of her medical practice.
This was my first visit with her, and I liked her very much.
Very professional and kind.
Dr. Fan is a wonderful doctor who knows about the medical concerns that I have. She is a very caring person.
I am very pleased with and have always been with Dr Fan. She’s very personable and knowledgeable. I trust her. Which is very important to me.
She conducts her self in a very professional manner, and I appreciate the way she conveys her patient care.
Doctor Alice is very professional, she really listened and seemed concerned about my father’s needs. THANK you Doctor Fan
very detail discussed all my DNA testing results and using the results to give all possible methods to prevent my cancer to return.
I've been very pleased with her thoroughness and understanding of my current issue.
Very good doctor and gave me a good understanding on my situation and how to handle.
She is very profesional , thank you!
very good.
Dr. Alice Fan, has fully explained all options for my condition; she has controlled my illness with medication.
A gorgeous physician
She was wonderful, very patient and an excellent communicator.
She was fantastic.
She was very helpful and presented the information in a way that I could easily understand.
What an incredible doctor and human being. I am so lucky to have Dr. Fan as my oncologist. So is Stanford.
I like Dr Fan very much, she is caring and thorough in her treatment of this patient.
Very empathetic
Very good person and doctor very knowledgeable
Dr Fan was very clear and concise. It was easy to understand her. She listened to my concerns and dealt with them.
I am very pleased with Dr Fan's attention to my case and her working with my local physician to provide me with the best treatment options possible in my locale. Thank you Dr Fan.
The notes were extremely helpful especially for the drug spelling and reactions the patient might experience. We are walking down a new road without any knowledge of what to expect. I liked to have some information about what will happen during my treatment.
She is an extremely caring and knowledgeable physician. I trust her very much.
Very good visit I feel very confident with Dr. Alice Fan
The BEST!!!
Very knowledgeable, easy to understand and made me aware of things that were relevant to my decision making going forward.
She's great! Give her a raise :-)
Very thorough and very considerate to my needs.
Excellent doctor
receptive, highly professional,excellent provider
I loved her optimism.
I am very happy with Dr. Fan, I think she is a very caring person!
She genuinely cares about her patients and listens to my concerns.
We like Dr. Alice Fan. She is friendly and has an outstanding personality.
Excellent dr.
Dr. Fan has a very high professional level. She is very amiable to patients. She is very worthy of the patients' trust and respect.
Dr. Fan has been very helpful with my husband's understanding of his cancer situation. She provides support with my husband's decision making about his future treatment of his metastatic kidney cancer. We both feel confident in her care and support. She was very patient with us and our poor connections.
very nice
SHE OFFERED TO CONNECT ME WITH A STANFORD CARIOLOGIST WHICH SHE DID AND I AM VERY GRATEFUL FOR HER PERFORMING THAT TASK.
I BROUGHT TO HER ATTENTION THAT MY PCP HAD DISAPPEARED AND I AM NOW WITHOUT ONE AND SHE HAS OFFERED TO CONNECT ME WITH A STANFORD PCP.
ALICE FAN IS A GREAT DOCTOR! I AM EXTREMELY FORTUNATE TO HAVE HER HELP ME WITH MY CANCER AND OTHER MEDICAL NEEDS.
She is fabulous.
She listens well to my concerns, and responds appropriately. Very easy to talk to. Seems to be extremely well-versed in her field. I feel extremely comfortable talking to her during the video visits. Would recommend her to anyone without hesitation.
She is the best!
Outstanding Dr.!!!
She is a good Docter.
She is so knowledgeable, helpful, forward-thinking and caring.
Always appreciate her knowledge and her ability to explain complex treatments in an understandable way. Her knowledge and confidence are soothing in the confusing world of navigating cancer.
Dr Fan is absolutely great
I want to repeat that Dr Fan was excellent in every way, and so was the person who began the video visit and asked me important questions, then shared my answers with Dr Fan, while I waited. She was well prepared and listened to all my concerns and answered them effectively.
Dr. Alice Fan was quite familiar with my past health record, explained efficiently my present health condition, steps to remove any uncertainties.
Quite pleased with my initial video visit with Dr. Fan !
She is very knowledgeable and easy to talk with. She seemed to care about my feelings.
Doc. Alice Fan Has always been very helpful and professional.
Dr. Fan is always prepared to discuss my case and answer any questions.
Very warm and friendly. Felt she listened very well to my concerns and questions. Offered and explained several treatment options thoroughly as well as offering referral possibilities.
Excellent, compassionate, professional
She is a genuinely caring and knowledgeable doctor. She has taken great care of me.
I have been very happy with Dr. Fans care
Dr. Fan is a wonderful caring doctor.
My video visit was delayed a bit, but I was told about it ahead of time by her assistant, so that was not a problem at all. Dr. Alice Fan was extremely pleasant to talk with and helpful in explaining my issues, and her plan was to help identify the source of my disease, which I thought was very novel, and hope would help take care of it for good.
Dr. Fan is a great oncologist and a very nice person.
She is a national asset. I trust her greatly with my care. Both my wife and myself very much cherish her advice and counsel. I am very grateful to have her on my team!
She was very thorough and listened to my concerns
Impressed and pleased with the visit.
She makes me feel comfortable when we talk about my situation. I am looking forward to talking to Dr. Fan again next week as we discuss our plan going forward.
Always great, very caring and understanding.
Dr. Fan has a high level of professionalism and is very nice to patients. I am very grateful to her.
Very helpful, knowledgeable, and explained everything very well.
Her sincere concern re; my situation.
Very friendly and concerned about my health.
I feel very fortunate to have Dr. Fan as my Oncologist. I can't say enough good things about Dr.Fan.I trust her completely. Hope to have her forever.
She's been very supportive and has explained all areas of treatment for me to have a better understanding of my condition and treatment plan. I appreciate her honesty and caring nature.
Dr Fan is very good and knowledgeable in what she does and I have a lot of confidence in her and the decisions she makes.
Excellent visit. Excellent Doctor.
An exceptional doctor. I trust her with my life.
Dr Alice Fan is very caring and very knowledgeable. I felt very good after talking to her.
She is a wonderful oncologist. I’m very happy to be working with her.
Good person , great doctor.
She is always proffesional and well spoken
Very knowledgeable Dr.
They're great Dr's ðŸ‘
Who listen very well .
They are very well Informed and truly care about my condition.
She is wonderful! I feel like I am in good hands.
Absolutely excelllent in terms of professionalism, knowledge base and interpersonal relations.
Absolutely a top notch professional! Alice graciously took the time to answer all are questions. We are so thankful for her insight and guidance.
Dr Fan has done a great job making the patient feeling as ease with her manner.
She seems genuine and caring and knowledgeable about the cancer and treatment. I would have been nice to see her face to make it more humane. Masks are intimidating and impersonal.
I have great trust in Dr. Fan
She is very knowledgeable in her field and also very caring. I feel lucky to have her as my doctor.
she does the best she can from over 200 miles away .
No other comments. I am very pleased.
Dr. Fan is always concerned how I am feeling and always ends with wanting to know if I got all my questions answered.
She’s great
Wonderful doctor, willing and able to get referrals in and procedures going. Compassionate and professional
Dr. Fan has my trust.
Knowledgable, compassionate, and a clear communicator. I'm very pleased with her professionalism.
she is an excellent doctor in my opinion she take care of my medical needs and answer my questions
Dr. Fan has clearly prepared for our appointment and has all the relevant data at her fingertips. Even better, she is compassionate and responsive to all our questions and concerns. We have complete confidence in her.
Excellent. Only 2nd video visit but she is friendly, caring and very respectful answered any questions we had. So happy to be with her team. Her RN is excellent as well
She seems excellent; knowledgeable, thorough and professional.
I felt confident about her expertise.
Stanford is fortunate to have her.
Besides being a brilliant Doctor, her confidence is so important to us in reducing the fear of the unknown. Navigating cancer treatments are frightening and confusing but Dr. Fan is always so thorough in her explanations and gives us her reasons behind the suggestions.
Very likeable
I felt Dr. Fan was outstanding in her knowledge and willing to defer to more experienced doctors with questions she wasn’t comfortable answering. That’s important to me because nobody knows it all. She is very warm and sympathetic.
Very transparent, answers fully with an engaging style. Top doctor!!!
What a wonderful Doctor! She was kind, compassionate and able to convey important information in a very understandable manner. Obviously highly intelligent, her demeanor was friendly and pragmatic, and she filled in all the informational bits and pieces that were of concern for me as she spoke to my issue at hand, such as who would be in contact with me moving forward, urgency of specific procedures etc. I felt much more informed, and educated after our appointment. Thank you so very much Dr. Fan!
She’s outstanding
Excellent Dr
She explained everything.
She's great
Her team has been wonderful thru this hard time.
She is an excellent uro oncologist. She explains everything and answers any questions you might have. She cares for her patients and her focus is to help them get better.
She’s great
She's a very good doctor.
Best medical experience of my life. I came away CALM and re-assured.
So far is --- "fantastic"!
Dr. Fan is tops. She really cares. I have all my trust in her.
Care provider is attentive to questions asked, and answer questions appropriately.
Great!! I am very glad I was able to meet, talk, review discuss my concern. Staff was very informative.
Dr. Alice Fan is awesome!
Excellent experience!
Dr. Fan is the best doctor I have ever seen. I trust her with my life.
Dr. Alice Chen-Fan has such a nice bed side manner. I feel totally comfortable with her treatment. She is good at following up on prior concerns/issues.
All providers seem well versed in care and needs.
All good.
Dr. Fan & her assistant made me feel safe. They explained everything and answered all my concerns. Their care is something that is sincere, and natural. I am so grateful for their care & knowledge.
Dr. Fan is a caring, friendly yet very professional doctor. Her demeanor instantly makes the patient feel comfortable and hopeful.
She (Dr. Fan) was honest, gentle & straight forward in her assessment & advice as to my husbands impending death.
Well informed staff.
Dr. Fan is amazing!
Very helpful, encouraging and informative.
This is my first visit with Dr. Fan and I was impressed with her effort to inform as well as to make me feel confident in her ability to help me get the best medical help.
Dr. Fan is wonderful in every way.
Very good.
I have an outstanding team and feel very fortunate.
Information helped me to decide to continue to seek treatment at facility.
Dr. Fan's care has been consistently wonderful. I'm very glad she's my doctor.
Dr. Fan is an amazing provider her compassion is beyond compare. She made you feel as if you were her only patient that day. Her physician assistant and RN were excellent also.
Dr. Fan was wonderful. Provided for me an excellent alternative treatment option. Will begin that treatment soon. Thank you Dr. Fan!
Excellent!!!
Very good.
We wouldn't be where we are today without the staff & Dr. Fan. Thank you!
Dr. Alice Fan is a very good care provider. I (100%) will refer my family and my friends for her good care -
I am very happy of the good care from Dr. Alice Fan and her staff. For sure, I will refer my family & friends to her -
View More
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records